
Becoming a leading global biotech company ranked in the top 25 by 2030
A global biotech company with a rich and diverse heritage
Founded in 1986 by Mr. P.V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, biotech company Aurobindo Pharma was born of a vision.

The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry, India. In addition to being the market leader in Semi-Synthetic Penicillin, Aurobindo Pharma has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Antibiotics.
Through cost effective manufacturing capabilities and several loyal customers, the company also entered the high margin specialty generic formulations segment. oday Aurobindo Pharma has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products.
150 Countries
Benefiting from our medicines

Aurobindo’s formulation business is systematically organised with a focused team for key international markets.
Leveraging its large manufacturing infrastructure for APIs and formulations, wide and diversified basket of products and confidence of its customers, Aurobindo achieved revenues of USD 3.3 billion in FY 2020-2021. Aurobindo’s 11 units for APIs and intermediates, and 15 units (10 in India, 3 in USA, 1 in Brazil, and 1 in Portugal) for formulations are designed to meet the requirements of both advanced as well as emerging market opportunities.
3.3 Billion
Revenue (2020-2021)

Aurobindo Pharma’s Evolution
Aurobindo Pharma’s Evolution
- Successful innovation in process chemistry
- Cost competitive manufacturing
- Large and diversified product portfolio
- Global leadership in anti-infectives
- Largest generic portfolio in Antiretroviral drugs (ARVs)

Aurobindo Pharma’s Evolution
Aurobindo Pharma’s Evolution
- Scale, Diversity and Leadership
- Operational Excellence
- Service Delivery
- Patient Focus

Robust research and development
Robust research and development
With one of the largest R&D facilities in India, Aurobindo Pharma has five research centres spread over 16,000 square meters. It also has 3 R&D centres in the USA. The biotech company employs over 1700+ scientists & analysts in-house with expertise in product development for ensuring quick turnaround times leading up to dossier submissions.